CD4+/CD56+ hematodermic neoplasm: report of a rare variant with a T-cell receptor gene rearrangement

J Cutan Pathol. 2008 Jun;35(6):579-84. doi: 10.1111/j.1600-0560.2007.00845.x. Epub 2007 Nov 12.

Abstract

CD4+/CD56+ hematodermic neoplasm (HN), formerly known as a blastic natural killer (NK) cell lymphoma, is a rare subtype of a cutaneous dendritic cell neoplasm notable for highly aggressive behavior. The characteristic features are: expression of the T-helper/inducer cell marker CD4 and the NK-cell marker CD56 in the absence of other T cell or NK-cell specific markers. In particular, CD3 (surface or cytoplasmic) and CD2 are not expressed. Although T-cell receptor (TCR) genes are generally reported to be in a germline configuration, we present an unusual variant of a CD4+/CD56+ HN with a clonal rearrangement of TCR genes. This feature of a CD4+/CD56+ HN has been only rarely reported. Recognition of the presence of clonal TCR gene rearrangements in a small subset of CD4+/CD56+ HN is important to avoid misdiagnosis of this entity as an unusual variant of a cutaneous T-cell lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis
  • CD4 Antigens / analysis*
  • CD56 Antigen / analysis*
  • Cyclophosphamide / therapeutic use
  • DNA, Neoplasm / genetics
  • Dexamethasone / therapeutic use
  • Doxorubicin / therapeutic use
  • Flow Cytometry
  • Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics*
  • Humans
  • Immunohistochemistry
  • Lymphoma, T-Cell, Cutaneous / chemistry
  • Lymphoma, T-Cell, Cutaneous / drug therapy
  • Lymphoma, T-Cell, Cutaneous / genetics
  • Lymphoma, T-Cell, Cutaneous / pathology*
  • Male
  • Middle Aged
  • Skin Neoplasms / chemistry
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / pathology*
  • Vincristine / therapeutic use

Substances

  • Biomarkers, Tumor
  • CD4 Antigens
  • CD56 Antigen
  • DNA, Neoplasm
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide

Supplementary concepts

  • CVAD protocol